NYSE · Healthcare

Pelthos Therapeutics Inc. (PTHS)

As-reported financials and recent SEC filings for Pelthos Therapeutics Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$16.8M

Net income

$-43.3M

Net margin

—

Diluted EPS

$-23.04

ROE

-111.4%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2023
Revenue	$16.8M	$0	—	—
Gross profit	$12.8M	—	—	—
Operating income	$-32.4M	$-7.6M	$-6.9M	$-2.3M
Net income	$-43.3M	$-8.0M	$-7.4M	$-2.5M
Diluted EPS	$-23.04	$-4.76	$-3.85	—

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-06-17

42026-06-15

8-K2026-05-28

42026-05-26

1442026-05-22

8-K2026-05-21

42026-05-18

SCHEDULE 13G/A2026-05-15

View on EDGAR →

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on PTHS

Search Pelthos Therapeutics Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.